Within four days in early March 2026, Lantheus Holdings, Inc. (Nasdaq: LNTH) collected two separate FDA regulatory milestones, one in radiopharmaceutical therapy, one in precision diagnostics, that together mark the most concentrated period of regulatory progress in the company’s recent history. On March 2, Lantheus received FDA tentative approval for the Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), making it the first radioequivalent to LUTATHERA® (lutetium Lu 177 dotatate) to clear the FDA’s review bar. On March 6, the FDA approved PYLARIFY TruVu™ (piflufolastat F 18), a new higher-throughput formulation of the company’s market-leading PSMA PET imaging agent for prostate cancer.
Taken together, the two actions reinforce Lantheus’ core strategic logic: become the integrated radiopharmaceutical platform that links diagnostic identification of cancer to targeted radiotherapeutic treatment, the company’s own shorthand of “Find, Fight, and Follow” disease.
PNT2003: The First Radioequivalent to Lutathera, Cleared in Principle
What PNT2003 Is and Why It Matters
PNT2003 is an ANDA-route version of lutetium Lu 177 dotatate, the peptide receptor radionuclide therapy (PRRT) approved as Lutathera (Novartis/Advanced Accelerator Applications) for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug consists of a somatostatin analog conjugated to the beta-emitting radioisotope lutetium-177 (Lu-177). Upon IV administration, the somatostatin analog component binds with high affinity to SSTR2 (somatostatin receptor subtype 2), which is frequently and densely overexpressed on GEP-NET cells. Receptor binding triggers internalization of the radiolabeled complex, delivering localized beta-minus radiation that causes DNA double-strand breaks and subsequent tumor cell apoptosis, directly within the tumor microenvironment, with limited systemic exposure.
The clinical case for Lu 177 dotatate rests principally on the NETTER-1 trial, which demonstrated a substantially improved PFS (20-month PFS 65.2% vs. 10.8% with high-dose octreotide LAR) and an 11.7-month numeric OS improvement, data that supported Lutathera’s original FDA approval in 2018 and have defined the PRRT standard of care in GEP-NETs since.
The OZM-067 trial (NCT02743741), a prospective single-arm multicenter study in 195 patients, evaluated PNT2003 specifically and demonstrated a 12-month PFS rate of 81% and an OS rate of 92% at 33 months, data that supported the ANDA submission and Lantheus’ radioequivalence arguments. Lantheus licensed exclusive worldwide rights to PNT2003 from POINT Biopharma in December 2022; POINT was subsequently acquired by Eli Lilly in December 2023.
Tentative Approval: What “Tentative” Means Here
The FDA tentative approval confirms that the agency has completed its technical review and that PNT2003 meets all statutory requirements for approval under the Federal Food, Drug, and Cosmetics Act. However, marketing clearance remains blocked pending the expiration of a 30-month regulatory stay, a standard Hatch-Waxman mechanism triggered by patent litigation with the reference listed drug holder. That stay is scheduled to expire in June 2026, at which point Lantheus will seek final approval and is positioned to launch commercially.
The distinction matters to investors and oncology practices tracking access timelines: the FDA’s scientific review is done, the drug is cleared on merit, and the delay is purely legal, not clinical or regulatory. Once the stay expires, Lantheus can proceed immediately to final approval and launch.
Mary Anne Heino, CEO of Lantheus, stated:
As the first radioequivalent to LUTATHERA to receive FDA tentative approval, PNT2003 marks an important step forward in Lantheus’ work to advance treatment options for patients with GEP-NETs. This milestone comes at a time when advances in imaging and evolving clinical guidelines are enabling the identification of more patients who stand to benefit from targeted radiopharmaceutical therapies.
Why GEP-NET Access to PRRT Is a Legitimate Patient Issue
GEP-NETs affect an estimated 200,000 patients in the U.S., with incidence rising steadily. Up to 50% are initially misdiagnosed, and the average patient waits 4.3 years from symptom onset to diagnosis, a delay that compounds treatment complexity. Access to PRRT has been constrained by limited manufacturing capacity and supply chain pressures around Lutathera. A regulatory-approved radioequivalent with independent manufacturing infrastructure addresses that constraint directly and at scale, a consideration that gives the PNT2003 approval practical patient-access significance beyond the commercial dimension.
PYLARIFY TruVu: Scaling the Most-Used PSMA PET Agent in the U.S.
What Changed and Why It Matters
PYLARIFY (piflufolastat F 18) is already the leading PSMA PET imaging agent in the U.S. by utilization, over 760,000 patients with prostate cancer have received PSMA PET scans with PYLARIFY since its FDA approval in May 2021. The FDA approval on March 6 was for PYLARIFY TruVu, a new formulation of the same compound designed with improved stability at higher radioactive concentrations, enabling larger batch production per manufacturing run and broader geographic distribution.
The reformulation does not alter PYLARIFY’s diagnostic performance, it preserves the established efficacy demonstrated in the OSPREY (n=385) and CONDOR (n=208) trials that supported the original approval, including median specificity of 96% for pelvic nodal and prostate gland lesion detection in OSPREY Cohort A. The approval was granted via the 505(b)(2) regulatory pathway, relying on that established clinical evidence base.
What changes is supply dynamics. A formulation that enables larger batches means more doses per manufacturing run, potentially reducing the geographic limitations that have constrained PYLARIFY access, particularly for patients in regions served by lower-throughput cyclotron-based production facilities. Lantheus has indicated PYLARIFY TruVu will be commercially available in Q4 2026 through a phased geographic rollout designed to minimize disruption to the existing customer base transitioning from PYLARIFY to TruVu.
Gina B. Carithers, President and CEO of the Prostate Cancer Foundation, framed the clinical significance:
With prostate cancer incidence expected to rise in the years ahead, it’s encouraging to see companies like Lantheus putting patients first and introducing innovations that help ensure timely, precise imaging while keeping pace with growing demand. Access to accurate diagnostics, especially when metastatic or recurrent disease is suspected, can profoundly impact both quality of life and long-term outcomes for people living with prostate cancer.
The Diagnose-to-Treat Architecture: Why Both Approvals Matter Together
The simultaneous momentum in PSMA PET imaging (PYLARIFY TruVu) and Lu-177–based targeted radionuclide therapy (PNT2003) is not coincidental, it reflects the structural logic of Lantheus’ platform strategy. PSMA PET imaging identifies prostate cancer that has metastasized to lymph nodes, bone, and soft tissue. That identification directly informs treatment selection, including eligibility for PSMA-targeted radioligand therapy. Lutathera/PNT2003 operates by the same detect-and-treat logic in GEP-NETs: somatostatin receptor scintigraphy (and increasingly Ga-68 DOTATATE PET) identifies receptor-positive tumors, and PRRT then delivers targeted radiation to those receptor-expressing cells.
In building both the diagnostic and therapeutic arms of the radiopharmaceutical value chain, Lantheus is constructing a business architecture that mirrors the precision oncology model at the molecular imaging level. With FY2025 revenue of $1.54 billion (including Q4 revenue of $406.8 million), Lantheus has demonstrated that this model can generate meaningful commercial scale.
Forward-Looking Analysis
June 2026 is the next pivotal date: the expiration of the Hatch-Waxman stay and Lantheus’ path to final PNT2003 approval and commercial launch. That event will be a genuine inflection point, the first competitive Lu-177 dotatate entrant in a market currently served exclusively by Lutathera. How Novartis responds, whether through pricing adjustments or supply enhancement, will be the competitive dynamic to watch.
On the PYLARIFY TruVu side, the Q4 2026 phased rollout will begin demonstrating whether larger-batch production translates into measurable access improvements, particularly in secondary and tertiary markets where PSMA PET availability has lagged academic centers. Prostate cancer incidence projections, nearly 334,000 new cases estimated in 2026 in the U.S. alone, make the imaging access story directly patient-relevant at scale.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada